The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 21, 12:33 AM

Slide #4. Celsion Corporation Secondary Offering

Company: Celsion Corporation (NASDAQ:CLSN)
Date announced: 1/10/2022
Shares Offered: 50,000
Date of Pricing: 1/10/2022
Price Per Share: $285.00
Secondary Offering Details: Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $285, representing an original issue discount of 5% of the $300 stated value of each share. Each share of Series A preferred stock is convertible into shares of Celsion's common stock at an initial conversion price of $0.91 per share. Each share of Series B preferred stock is convertible into shares of Celsion's common stock at an initial conversion price of $1.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of stockholder approval for a reverse stock split of the Company's common stock. Celsion will be permitted to compel conversion of the Series A and Series B preferred stock after the fulfillment of certain conditions and subject to certain limitations. Total net proceeds from the offerings, before deducting the placement agent's fees and other estimated offering expenses, is approximately $28.5 million.

Celsion is a clinical stage biotechnology company focused on developing a portfolio of treatments including DNA-based immunotherapies, vaccines and chemotherapies. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for ovarian cancer treatment and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is under investigator-sponsored development for several cancer indications. Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Open the CLSN Page at The Online Investor »

Company Name: 
Celsion Corp
Drugs & Pharmaceuticals
Number of ETFs Holding CLSN: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the CLSN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CLSN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
18th percentile
(ranked lower than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.